Case Report

Significant Clinical Manifestations in Ballantyne Syndrome, after a Case Report and Literature Review: Recognizing Preeclampsia as a Differential Diagnosis

Silvia F. Navarro-Perez,¹ Karen Corona-Fernandez,² José L. Rodriguez-Chavez,³ A. Bañuelos-Franco,³ and María G. Zavala-Cerna²

¹Unidad de Investigación en Ginecología y Alto Riesgo Obstrótico, División de Ginecología y Obstetricia del Hospital General de Occidente, Av. Zoquitán #1050, Col. Seattle, 45170, Mexico
²Immunology Research Laboratory, International Program of Medicine, Universidad Autónoma de Guadalajara, 44100, Mexico
³Unidad de Investigación en Ginecología y Alto Riesgo Obstrótico, División de Ginecología y Obstetricia del Hospital General de Occidente, Mexico

Correspondence should be addressed to María G. Zavala-Cerna; gzavala78@hotmail.com

Received 1 October 2018; Revised 30 January 2019; Accepted 17 February 2019; Published 5 March 2019

Academic Editor: Maria Grazia Porpora

Copyright © 2019 Silvia F. Navarro-Perez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ballantyne syndrome (BS) also called mirror syndrome is defined by the presence of a clinical triad that includes fetal hydrops and placental and maternal edema. Here we present a clinical case of a 34-year-old woman with a 29 weeks' pregnancy, who developed BS and fetal loss probably due to failure in prompt recognition of a rapidly growing sacrococcygeal teratoma (SCT). Due to similarities in clinical presentation with preeclampsia and the importance in early identification of the source for BS, we underwent a literature review in order to identify significant signs and symptoms, as well as sonographic changes, in order to help clinicians to make this prompt recognition, identification of the cause, and early management of BS, which will have an important impact in maternal and fetal survival.

1. Introduction

Ballantyne syndrome (BS) also called mirror syndrome or triple edema is defined by the presence of a clinical triad that includes fetal hydrops and placental and maternal edema [1]. The term mirror as the name implies is due to an edema that is mirrored in both, the fetus and the mother [2]. John William Ballantyne in 1892 was the first to acknowledge the syndrome, originally thought to be the consequence of rhesus isoimmunization; however currently more than 80 different causes have been described and not all of them have an immunological origin [3], with only a few reported cases [4]. The syndrome appears in one out of 3,000 pregnancies; however the incidence can be underestimated, due to similarities in clinical presentation with preeclampsia (PE) [1, 3], which include maternal edema (80-100%), hypertension (60%), proteinuria (20-56%), anemia (46%), rapid weight gain, progressive dyspnea, and albuminuria [5]. Unlike preeclampsia in BS patients are hemodiluted according to blood indices with a typical low hematocrit [6]. In addition to similarities in their clinical presentation, preeclampsia and BS can coexist and compromise to a greater extent pregnancy resolution, as well as the maternal and fetal prognosis. In preeclampsia the recognition of abnormal placentaion with defective spiral artery remodeling, favoring progressive placental ischemic reperfusion and excessive oxidative stress has been clearly established [7]. These changes result in a pathological imbalance among angiogenic (VEFG) and anti-angiogenic circulating factors (sFlt, activin) [8]. On the contrary, the etiology and pathogenic mechanisms in BS are still partially described and remain unclear, probably due to a limited number of papers [9]. Some factors that have been previously associated with the development of BS include diverse conditions, such as nonstructural causes:
rhesus isoimmunization, fetal supraventricular tachycardia, vertical cytomegalovirus, parvovirus B19 and Coxsackie virus infection, and laser photocoagulation for twin-to-twin transfusion syndrome, as well as structural alterations: aneurysm of Galen's vein, sacrococcygeal teratoma (SCT), or placental chorioangioma [10, 11].

It is extremely important for clinicians to identify similarities and differences between BS and preeclampsia, since diagnosis and management of BS might be possible when the source is readily identified [3]. Here, we present a case report of BS probably secondary to SCT that was not promptly identified. Additionally, we underwent a literature review to identify clinical similarities and differences between preeclampsia and BS, in order to provide hallmarks for prompt recognition and treatment of the base pathology that is responsible for BS, which will decrease maternal and newborn fatalities.

2. Case Report

A 34-year-old woman gravida 5, para 3, abortion 1 presented to the ER of our hospital, at 29 weeks' gestation, due to uterine contractions that increased in frequency and intensity in the last 5 hours, with no other symptomologies added (Figure 1). Her past medical history was unremarkable with O + hemotype; she had an abortion due to an anembryonic pregnancy that required curettage, which was performed without complications. The patient had 3 healthy previous pregnancies which resulted in 3 healthy living children. Currently in her fifth pregnancy, she denies pregnancy care; only one obstetric ultrasound performed at 24 weeks' gestation in another clinic reported the following: harmonic fetal growth and no fetal malformations; however polyhydramnios was present. During her observation in the ER, a new ultrasound examination was ordered, which revealed an apparently large placenta with approximate weight of 1,800 gr, suggestive of placental edema; the fetus appeared with polyhydramnios, and no heartbeats nor fetal movements were registered; she was then referred to the high risk obstetric department, where she was found to have normal vital signs, mild edema of the ankles without fovea, and a gravid uterus occupied by a single longitudinal cephalic fetus with lateralized back to the left; fetal heart rate was not detected with doptope; she had regular uterine dynamics palpable at a rate of 3 contractions lasting 60 seconds each, within a time frame of 10 minutes; at vaginal examination the cervix was softened with 4 cm of dilation and 70% thinned, intact amniotic membranes, without bleeding or leucorrhoea. Laboratory tests reported the following: hemoglobin 11.5 g/dl, hematocrit 34.8%, and no other abnormal results including normal renal and hepatic function. Due to increased frequency of contractions, she was immediately sent to the expulsive room, where a single female sex without vitality was spontaneously delivered, with data of hydrops and macerated skin, weight: 1,730 gr, with a grayish and hemorrhagic sacral mass (Figure 2). After resection of the tumor and pathologic examination the following report was made: An 820 gr Type I sacrococcygeal teratoma (SCT) with mature and immature elements as well as blood sequestration areas, partially encapsulated with extensive areas of coagulation and necrosis. Placenta was grossly edematous and weighed 1,280 gr with a marked hydropic change of the villi, with an area of intervillous fibrinoid infarct was noticed. Amnion and chorion had no alterations. The umbilical cord had three blood vessels with marked edema of Wharton's jelly. The patient received counseling and was discharged 3 days after delivery without edema or any other physical alteration.

3. Discussion

In the present case, the diagnosis of BS was established after the findings of fetal hydrops, placental edema, and mild maternal edema. Presumably in this case, BS developed secondary to SCT. The SCT was not evident in the first ultrasound at 24 weeks' gestation, neither were fetal hydrops; however polyhydramnios was present at that time. SCT is a rare congenital disease of the newborn that happens in 1 out of 20,000-40,000 pregnancies, predominantly in female newborns with a ratio of 3:1 [12]. The perinatal mortality of SCT has been estimated from 40 to 50% [13]. Death occurs in fetuses with fast growing, solid, and highly vascularized teratomas which can originate high-output cardiac failure, which is a consequence of the tumor acting as a large arteriovenous malformation that steals vascular supply from the fetus [14]. Goto et al. published the report of two cases of SCT in which only one was associated with BS and a fetal outcome for the fetus [15].

The etiopathogenic mechanisms of BS remain partially understood; it has been suggested that the placenta is the source of the problem, since resolution of the pregnancy with the removal of the placenta resolves the mirroring edema [16]. Some previous reports have stated that compensatory mechanisms originate as a consequence of placental ischemia and are responsible for an increased placental blood flow with a rise in placental renin up to 10-fold, which will aid in increased maternal aldosterone a fluid retention [17]. Furthermore, some molecules have been identified in association with endothelial dysfunction in BS, such as Activin A and follistatin; other molecules are involved in inflammation and increased vascular permeability including ICAM-1 and vWF; the potent vasoconstrictor ET-1 [10]; and the anti-angiogenic factor sVGEFR-1 [18]. Nevertheless, it would be of interest to determine the abnormalities in the fetus that will later give rise to these alterations in the placenta that finally manifest in BS, which is a life threatening condition for the mother and the fetus [19].

In the fetus, the development of hydrops secondary to SCT can be explained by a high output failure caused by either anemia due to tumor hemorrhage and/or an arteriovenous shunt in a low resistance, rapidly growing tumor [20, 21]. Cardiac failure can give rise to an alteration in the regulation of the fluid dynamics between vascular and interstitial spaces, with an imbalance of interstitial fluid production and lymphatic return, which will eventually lead to fetal hydrops [19]. The fetus is particularly susceptible to interstitial fluid accumulation because of its greater capillary permeability compliant interstitial compartments.
34-year-old female with a 29 weeks’ gestation pregnancy. Presents with uterine contractions that increased in frequency and intensity in the last 5 hours.

Vital signs: PA 110/70 (mmHg), HR 84 hbpm, RR 17 rpm, Temp 36ºC. No fetal cardiac sounds or movements.

Contractions increase in frequency and intensity: 3 contractions, lasting 60 seconds in 10 minutes.

Softened cervix with 4cm of dilation and 70% effacement, amniotic membranes without rupture

New ultrasound revealed:

- Phelan Index: 30 cc PCA GII
- Large placenta: weight 1800 grams (Normal <750 g)
- No fetal movements nor heartbeats
- Polyhydramnios

Obtaining:

- Single non-viable female product with hydrops and macerated skin. Weight: 1730 g
- A grayish sacral mass was observed in the sacral region

Histological examination of the tumor: Type I sacrococcygeal teratoma with areas of necrosis.

Placental: macroplacenta with marked hydropic change of the villi

G5, P3, A1 with unremarkable pathological history, hemotype O+. A previous ultrasound at 24 weeks’ gestation was unremarkable except for polyhydramnios.

CBC with dilutional anemia and low hematocrit (34.8%).

Blood urea 24, uric acid 4.8

HbAic:4.8, Alpha fetoprotein:20,381, and chorionic gonadotropin hormone: 630.1

5U oxytocin in Hartmann solution from 1000 cc to 30 ml / hr in continuous infusion pump

First Hour

Second Hour

EXPULSIVE (4 hours)

RECOVERY AREA

Post-partum physical: without abnormalities

New laboratory exams: HbAic-4.8, Alpha fetoprotein-20,381, and chorionic gonadotropin hormone: 630.1

No postpartum obstetric complications, estimated bleeding of 150 cc

Histological examination of the tumor: Type I sacrococcygeal teratoma with areas of necrosis. Placental macroplacenta with marked hydropic change of the villi

Figure 1: Timeline of patient’s clinical evolution with diagnostic tests and treatments. SCT: sacrococcygeal teratoma.

and vulnerability to venous pressure on lymphatic return. Compensatory mechanism to maintain homeostasis during hypoxia results in increased venous pressure and interstitial fluid accumulation, developing the characteristic hydropic changes [22]. In our case the histologic examination of the tumor demonstrated signs of bleeding; nevertheless the presence of an arteriovenous shunt was not examined. The presence of fetal hydrops in our case was evident at delivery, established by accumulation of fluid in the skin and abdomen (Figure 2), in accordance with fetal hydrops definition [23].

Furthermore, rapid growth of SCT (>150 cm³ per week) and hypervascularity are associated with increased risk in perinatal mortality [12]. A previous study stated that SCT bigger than 5 cm can be involved in the formation of high volume arteriovenous shunts that can lead to cardiac failure, placentomegaly, hydrops, and preeclampsia or BS [14]. This seems to be in accordance with our case; although the growth of the tumor was not registered by week, it was evident that most of the growth happened after 24 weeks’ gestation and before 29 weeks’ gestation.
Differential Diagnosis. When establishing a differential diagnosis, it is important to acknowledge that the most common complications in pregnancy are hypertensive disorders such as preeclampsia with an estimated prevalence of 10-12% worldwide; nevertheless, it may coexist with other pathologies including BS. It is yet to be determined whether the treatment of the underlying cause of BS could improve preeclampsia as well.

In order to distinguish BS from preeclampsia, one important variable is time for presentation since BS can present earlier, with the first becoming evident as soon as 16 weeks’ gestation and the latter presenting after 20 weeks’ gestation [1]. Please refer to Table 1 in order to compare this and other considerations for each pathology.

Maternal rapid weight gain, marked skin edema, and uterine distention can also be distinguishable features in BS, whereas elevated blood pressure and proteinuria can be present in both [11]. Although maternal edema is an important clinical consideration, our case presented with only mild maternal edema; we found only few cases where maternal edema could be absent or mild in BS secondary to SCT [11].

Renal failure can appear in both; however, it has been described in a higher frequency for BS; postpartum hemorrhage and pulmonary edema have also been described in BS [24]. Other unspecific findings common to both include headache, nausea, vomiting, dyspnea, oliguria, pulmonary edema, anemia, elevated uric acid/creatinine, and elevated liver enzymes [25]. Laboratory findings of special interest for differential diagnosis are a dilutional anemia with low hematocrit, thrombocytopenia, and low serum albumin which are characteristic of BS, whereas in preeclampsia patients typically present with hemoconcentration [1, 26]. Dilutional anemia and thrombocytopenia in BS might be explained through the finding of high maternal serum vasopressin and atrial natriuretic factor [11].

First-trimester uterine artery Doppler ultrasound examination, placental growth factor, and pregnancy-associated plasma protein A help to predict pregnancy complications associated with uteroplacental insufficiency such as preeclampsia before the onset of clinical features [27]. Also, during ultrasound examination in BS the most common fetal findings are hydrops fetalis (involving peritoneal compartment, cutaneous compartment, pleural space, pericardial space, and fetal scalp), polyhydramnios, placental edema, fetal anomalies, organomegaly, or a tumor, alone or simultaneously [1].

Development of BS can increase the risk of preeclampsia and vice versa; we believe that there is a common ground for the development of both pathologies, a ground that favors an angiogenic-antiangiogenic imbalance that might contribute to an even worse prognosis when both entities coexist; therefore it is mandatory to alert physicians about this possibility in order to remain vigilant and prescribe early treatment when indicated.

Treatment. BS syndrome should be treated accordingly to the source or the reason for the endothelial dysfunction. Placental or fetal malignancies are rare complications during pregnancy, but when they occur, they may present significant challenges. In our case SCT was identified as the possible source for BS. The importance in this association is that SCT diagnosed prenatally can be managed to avoid fetal fatalities [14]. Fetal surgery of SCT is a viable option for treatment in selected patients that demonstrate signs of cardiovascular decline during gestation, or when the mother is at risk [28]. Beyond 27 weeks’ gestation, however, the risk for the development of complications related to the surgery increases significantly; therefore early delivery (27 to 32 weeks’ gestation) with immediate SCT resection has been shown to be a better option than “watchful waiting” documented by Baumgartner et al. with a survival rate of 81.8% [13]. Important considerations for the success of earlier delivery include a low compromised hydropic fetus, absence of high-output cardiovascular failure, absence of tumor bleeding or fetal anemia, and having appropriate facilities for neonatal intervention and immediate surfactant administration [13].

Maternal complications of BS, such as hypertension and pulmonary edema, should be immediately treated if there is a decision to wait with continuous observation and the administration of diuretics, calcium channel blockers, and beta-blockers [29].

4. Conclusions

We presented a case report with BS probably following to the development of SCT after 24 weeks’ gestation, with polyhydramnios, hydrops fetalis, placental edema, and mild...
| Variable                        | PE Maternal | BS | Case Report |
|--------------------------------|-------------|----|-------------|
| Gestational age                | < 20        | 16-34 | 24-29       |
| Edema                          | ++          | ++  | +           |
| Hypertension (> 130/80)        | +++         | +   | -           |
| Proteinuria (> 300mg/day)      | +++         | +   | +           |
| Hypertension (OTR)             | +           | -   | -           |
| Liver function test abnormalities | +++       | +   | +           |
| Creatinine                     | ++          | +   | +           |
| Urea                           | ++          | +   | +           |
| Creatinine:urea ratio          | ++          | +   | +           |
| Thrombocytopenia               | +++         | +   | -           |
| Uterine bleeding               | ++          | +   | -           |
| Renal failure                  | ++          | +++ | -           |
| Pulmonary edema                | +           | +++ | -           |
| Anemia                         | Hemoconcentration | Hemodilution | Hemodilution |
| Placental edema                | -           | +++ | +++         |
| Fetal                          |             |     |             |
| Hydrops                        | +           | +++ | +++         |
| Polyhydramnios                 | +           | +++ | +++         |
| Cardiac affection              | +           | ++  | Unknown     |
| Intrauterine growth restriction| +           | -   | -           |
| Associated tumor               | -           | +   | +           |
| Fetal death                    | +           | ++  | ++          |

maternal edema. Since the most common cause for the development of hydrops fetalis is preeclampsia, we thought it could be important to identify clinical differences that could help in a prompt diagnosis since management of both entities is different, especially in BS where the source for endothelial dysfunction can be recognized prenatally. Preeclampsia and BS share some similarities in clinical presentation; even more, they can occur simultaneously, increasing the risk of maternal and fetal death. Some clinical considerations that point towards BS in the mother are time of onset (<20 weeks), edema, renal affection, and hemodilution; in the fetus, ultrasound examination: polyhydramnios, cardiac affection, and fetal anomalies, including tumors. Finally, we would like to emphasize that in our case the initial manifestation was polyhydramnios; therefore, it is mandatory that patients with this abnormality are adequately observed during the following weeks’ gestation with a Doppler ultrasound or fetal MRI for the evaluation of hydrops fetalis, and, in the case of a tumor, growth rate and vascularity. Then, each case should be evaluated for either early termination of pregnancy or fetal surgical intervention, in order to decrease the risk of fetal mortality, as well as maternal morbidity and mortality associated to BS.

Additional Points

Highlights. (i) Ballantyne syndrome and preeclampsia have different etiologies but similar clinical presentations; (ii) identification of significant clinical differences between both will contribute to accurate prompt diagnosis; (iii) prompt treatment of BS will have a beneficial impact in maternal and fetal survival.

Consent

Informed consent was obtained from the patient; her personal data was protected always, during the elaboration and publication of the manuscript.

Disclosure

This article does not contain studies with human participants or animal subjects of experimentation.

Conflicts of Interest

The authors declare that they have no conflicts of interest.
Authors’ Contributions

Silvia F. Navarro-Perez, Karen Corona-Fernandez, and María G. Zavala-Cerna were responsible for gathering information; Silvia F. Navarro-Perez, Karen Corona-Fernandez, María G. Zavala-Cerna, José L. Rodríguez-Chavez, and A. Bañuelos-Franco carried out the analysis of the information and medical literature; Silvia F. Navarro-Perez, Karen Corona-Fernandez, José L. Rodríguez-Chavez, A. Bañuelos-Franco, and María G. Zavala-Cerna were responsible for draft writing and approval of the final version; María G. Zavala-Cerna was responsible for data submission.

References

[1] S. Allarakia, H. A. Khayat, M. M. Karami et al., “Characteristics and management of mirror syndrome: a systematic review (1956–2016),” Journal of Perinatal Medicine, vol. 45, no. 9, pp. 1013–1021, 2017.
[2] D. Y. Midgley and K. Harding, “The mirror syndrome,” European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 88, no. 2, pp. 201-202, 2000.
[3] D. V. Valsky, H. Daum, and S. Yagel, “Reversal of mirror syndrome after prenatal treatment of Diamond-Blackfan anemia,” Prenatal Diagnosis, vol. 27, no. 12, pp. 1161–1164, 2007.
[4] S. Ren, T. Bhavsar, and J. Wurzel, “CHAOS in the mirror: Ballantyne (mirror) syndrome related to congenital high upper airway obstruction syndrome,” Fetal and Pediatric Pathology, vol. 31, no. 6, pp. 360–364, 2012.
[5] A. Brandão, A. Domingues, E. Fonseca, T. Miranda, and J. Moura, “Mirror syndrome after fetoscopic laser treatment - a case report,” Revista Brasileira de Ginecologia e Obstetricia, vol. 38, no. II, pp. 576–579, 2016.
[6] R. B. Gherman, M. H. Incerpi, D. A. Wing, and T. M. Goodwin, “Ballantyne syndrome: Is placental ischemia the etiology?” The Journal of Maternal-Fetal and Neonatal Medicine, vol. 7, no. 5, pp. 227–229, 1998.
[7] J. W. Meekins, R. Pijnenborg, M. Hanssens, J. R. McFadyen, and A. van Asseh, “A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies,” British Journal of Obstetrics and Gynaecology, vol. 101, no. 8, pp. 669–674, 1994.
[8] R. J. Levine, S. E. Maynard, C. Qian et al., “Circulating angiogenic factors and the risk of preeclampsia,” The New England Journal of Medicine, vol. 350, no. 7, pp. 672-83, 2004.
[9] J. Y. Lee and J. Y. Hwang, “Mirror syndrome associated with fetal leukemia,” Journal of Obstetrics and Gynaecology Research, vol. 41, no. 6, pp. 971–974, 2015.
[10] S. R. Hobson, E. M. Wallace, Y. F. Chan, A. G. Edwards, M. W. Teoh, and A. P. Khaw, “Mirroring preeclampsia: the molecular basis of Ballantyne syndrome,” The Journal of Maternal-Fetal & Neonatal Medicine, pp. 1–6, 2019.
[11] T. Braun, M. Brauer, I. Fuchs et al., “Mirror syndrome: a systematic review of fetal associated conditions, maternal presentation and perinatal outcome,” Fetal Diagnosis and Therapy, vol. 27, no. 4, pp. 191–203, 2010.
[12] R. D. Wilson, H. Hedrick, A. W. Flake et al., “Sacrococcygeal teratomas: prenatal surveillance, growth and pregnancy outcome,” Fetal Diagnosis and Therapy, vol. 25, no. 1, pp. 15–20, 2009.
[13] H. D. Baumgarten, J. S. Gebb, N. Khalek et al., “Preemptive delivery and immediate resection for fetuses with high-risk sacrococcygeal teratomas,” Fetal Diagnosis and Therapy, pp. 1–8, 2018.
[14] J. C. Langer, M. R. Harrison, K. G. Schmidt et al., “Fetal hydrops and death from sacrococcygeal teratoma: Rationale for fetal surgery,” American Journal of Obstetrics & Gynecology, vol. 160, no. 5, pp. 1145–1150, 1989.
[15] S. Goto, N. Suzumori, S. Obayashi, Y. Ozaki, and M. Sugihara-Ogasawara, “Two cases of prenatally diagnosed sacrococcygeal teratoma type I with different clinical features,” Congenital Anomalies, vol. 53, no. 2, pp. 92–94, 2013.
[16] S. Hayashi, H. Sago, R. Hayashi et al., “Manifestation of mirror syndrome after fetoscopic laser photocagulation in severe twin-twin transfusion syndrome,” Fetal Diagnosis and Therapy, vol. 21, no. 1, pp. 51–54, 2005.
[17] D. M. Paternoster, F. Manganeli, D. Minucci et al., “Ballantyne syndrome: a case report,” Fetal Diagnosis and Therapy, vol. 21, no. 1, pp. 92–95, 2005.
[18] J. Espinoza, R. Romero, and J. K. Nien, “A role of the anti-angiogenic factors VEGFR-1 in the ‘mirror syndrome’ (Ballantyne’s syndrome),” The Journal of Maternal-Fetal and Neonatal Medicine, vol. 19, no. 10, pp. 607–613, 2006.
[19] T. Van Mieghem, A. Al-Ibrahim, J. Deprest et al., “Minimally invasive therapy for fetal sacrococcygeal teratoma: case series and systematic review of the literature,” Ultrasound in Obstetrics & Gynecology, vol. 43, no. 6, pp. 611–619, 2014.
[20] A.-X. Holtermann, D. Filiatrault, M. Lallier, and S. Youssef, “The natural history of sacrococcygeal teratomas diagnosed through routine obstetric sonogram: a single institution experience,” Journal of Pediatric Surgery, vol. 33, no. 6, pp. 899–903, 1998.
[21] S. J. Bond, M. R. Harrison, K. G. Schmidt et al., “Death due to high-output cardiac failure in fetal sacrococcygeal teratoma,” Journal of Pediatric Surgery, vol. 25, no. 12, pp. 1287–1291, 1990.
[22] C. Bellini and R. C. Hennekam, “Non-immune hydrops fetalis: a short review of etiology and pathophysiology,” American Journal of Medical Genetics Part A, vol. 158A, no. 3, pp. 597–605, 2012.
[23] X. González-De Chirivella, D. Silva-García, M. Rivas-Gómez, and C. Medina-Gómez, “Diagnóstico prenatal de hidrops fetal no inmu: Serie de nueve casos. Revisión de la literatura,” Revista Colombiana de Obstetricia y Ginecología, vol. 63, pp. 148–154, 2012.
[24] R. M. Burwick, R. A. Pilliod, S. E. Dukhovny, and A. B. Caughhey, “Fetal hydrops and the risk of severe preeclampsia,” The Journal of Maternal-Fetal and Neonatal Medicine, pp. 1–5, 2017.
[25] G. Hirata, S. Aoki, K. Sakamaki, T. Takahashi, F. Hirahara, and H. Ishikawa, “Clinical characteristics of mirror syndrome: a comparison of 10 cases of mirror syndrome with non-mirror syndrome fetal hydrops cases,” The Journal of Maternal-Fetal and Neonatal Medicine, vol. 29, no. 16, pp. 2630–2634, 2016.
[26] R. Iciek, M. Brązert, A. Klejewski, M. Pietryga, and J. Brązert, “Ballantyne syndrome (the Mirror syndrome) associated with severe non-immune fetal hydrops – a case report,” Polish Gynaecology, vol. 86, no. 9, pp. 706–711, 2015.
[27] S. L. Khong, S. C. Kane, S. Brennecka, and F. da Silva Costa, “First-trimester uterine artery Doppler analysis in the prediction of later pregnancy complications,” Disease Markers, vol. 2015, Article ID 679730, 10 pages, 2015.
[28] N. S. Adzick, T. M. Crombleholme, M. A. Morgan, and T. M. Quinn, “A rapidly growing fetal teratoma,” The Lancet, vol. 349, no. 9051, p. 538, 1997.
[29] C. Brochet, P. Collinet, N. Provost, and D. Subtil, “Mirror syndrome due to parvovirus B19 hydrops complicated by severe maternal pulmonary effusion,” *Prenatal Diagnosis*, vol. 26, no. 2, pp. 179-180, 2006.
